MHRA restricts Protelos indications and adds new cardiovascular warnings

In light of cardiovascular safety concerns, the MHRA has limited use of the osteoporosis treatment Protelos (strontium ranelate) to severe cases of osteoporosis.

The reduction in bone density seen in osteoporosis increases the risk of a fracture occurring | SCIENCE PHOTO LIBRARY
The reduction in bone density seen in osteoporosis increases the risk of a fracture occurring | SCIENCE PHOTO LIBRARY

To minimise the risk of serious heart problems, Protelos (strontium ranelate) should now only be used for severe osteoporosis in postmenopausal women at high risk of fracture and men at increased risk of fracture.

Analysis of randomised controlled trial data has shown that strontium is associated with an increased risk of myocardial infarction and other serious cardiac disorders (relative risk 1.6 vs placebo [95% CI 1.07–2.38]).

The MHRA advises that strontium should only be started by a physician experienced in the treatment of osteoporosis. Clinicians should assess cardiovascular risk before starting strontium and at regular intervals during treatment and should base their decision to prescribe the drug on the individual patient’s risks.

In addition, strontium is now contraindicated in patients with ischaemic heart disease, peripheral artery disease or cerebrovascular disease (or a history of these conditions) and in those with uncontrolled hypertension. Treatment should be stopped if any of these conditions develop.

The prescribing advice for strontium was previously changed after concerns about an increased risk of venous thromboembolism and serious skin reactions arose in March 2012.

View Protelos drug record

MHRA Drug Safety Update April 2013

Follow MIMS on Twitter

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

More from MIMS

A woman wearing a white vest as a blue-gloved hand of a healthcare professional are seen injecting a vaccine.

'Nocebo' effect may cause two-thirds of COVID-19 vaccine reactions, study suggests

Two-thirds of adverse reactions reported with the COVID-19...

An elderly woman with one arm in a plaster cast sits resting both hands on her walker

Doctors urge NICE to reverse decision on new osteoporosis drug

More than NHS 100 clinicians have called on NICE to...

Drug shortages - live tracker

Use our constantly updated shortages tracker to check...

Image of both strengths of Seffalair Spiromax inhaler side by side.

New salmeterol/fluticasone dry powder inhaler for asthma

Seffalair Spiromax is the sixth dry powder salmeterol/fluticasone...